Key biomarker differences between gastric versus EGJ adenocarcinoma (KINGCA Week 2026) - Oct 11, 2026 - Abstract #SP13-2; Pres time: Sep 19, 2026; 09:20 AM - 09:40 AM; Location: Room C; "PD-L1 expression, while present in both subtypes, trends higher in GEJ tumors in several cohorts, directly influencing eligibility for checkpoint inhibitor therapy (e.g., pembrolizumab, nivolumab). These molecular distinctions are not merely academic: they inform HER2-targeted therapy selection, immunotherapy eligibility, prognosis, and clinical trial stratification. As precision oncology continues to shape gastric and GEJ cancer management, recognizing site-specific biomarker patterns is essential for optimizing individualized treatment strategies."
Biomarker • IO biomarker • Epstein-Barr Virus Infections • Esophageal Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Microsatellite Instability • Oncology • Solid Tumor • MSI • NTRK • PD-L1
|